Denver Firm Received Grant for Glioblastoma Drug Trial
The National Cancer Institute will fund research into an experimental treatment for recurrent brain tumors.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you trust that government-funded medical research leads to affordable new treatments for patients?
Numiera Therapeutics has been awarded a $2.3 million grant by the National Cancer Institute to study the drug etomoxir. This funding will support an early-phase clinical trial for patients with recurrent glioblastoma.
Why it matters
Glioblastoma remains a challenging form of brain cancer, and this trial aims to establish safety, dosage, and biological activity for a new therapeutic approach. This research represents a step toward developing potential options for patients whose disease has returned.
The National Cancer Institute awarded grant 1R44CA310352-01 to support a dose-escalation and window-of-opportunity trial. While Numiera Therapeutics has completed Phase I safety data, efficacy in humans is not yet established.
The players
Numiera Therapeutics
A Denver-based biotechnology firm focused on developing novel treatments for glioblastoma.
National Cancer Institute
The federal agency responsible for cancer research, training, and the dissemination of information.
The details
Etomoxir functions as a CPT1 inhibitor, targeting the metabolic processes that malignant cells may rely on for survival. The planned study will examine how the drug interacts with tumor tissue in the brain to determine the maximum tolerated dose and assess potential therapeutic signals in patients.
Timeline
September 21, 2026: Numiera Therapeutics announced the receipt of the grant award.
Health Landscape
This grant follows the long-standing mission of the National Cancer Institute SBIR program to bridge the gap between laboratory discovery and clinical application for advanced cancers. The project aims to transition etomoxir from preclinical validation toward potential later-phase trials.
Patients and families affected by recurrent glioblastoma should note that this is an early-phase trial in the development pipeline. Any questions regarding the appropriateness of clinical trial participation should be directed to a neuro-oncologist.
The takeaway
The development of CPT1 inhibitors like etomoxir represents an ongoing effort to disrupt the metabolic pathways used by aggressive brain tumors. Patients interested in trial availability should discuss clinical research options and current standards of care with their treating physician.
Further reading
For more information on the current state of neuro-oncology and treatment development, visit the Cancer section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that government-funded medical research leads to affordable new treatments for patients?
